The institute will join the NCI's Cancer Systems Biology Consortium, which is studying cancer initiation, progression, and metastasis.
OHSU was granted the rights to offer Biocept's Target Selector liquid biopsy testing services in Oregon as part of the deal.
The Seattle-based firm is working with Oregon Health & Science University researcher Lisa Coussens on a tool for studying the innate immune system in oncology.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
Researchers performed metagenomic sequencing on sea samples from two ocean voyages to uncover double-stranded DNA virus communities at sites around the world.
The Ontario Institute for Cancer Research will work with prostate cancer data while Dana Farber Cancer Institute's pilot has yet to be decided.
The partners will work on pilot projects that use novel analytical approaches to explore oncology molecular and imaging data.
The company said it plans to launch a clinical trial to validate its Immray PanCan-d blood test in both Europe and the US.
The partners will try to validate the Immray PanCan-d array-based test, which looks at proteins associated with the immune response to pancreatic cancer.
The organizations will create an integrated omics laboratory to investigate disease biomarkers for new drug therapies.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.